Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study. The COBRA study was designed to evaluate the effectiveness of using MRD testing to improve clinical outcomes in patients with stage…
Click here to view original post